BEGIN:VCALENDAR
VERSION:2.0 
PRODID:-/-/EN
BEGIN:VEVENT
SUMMARY:Society Symposium 'Right Test, Right patient, Right Response:..', Presidential Address & AGM
UID:1169
DESCRIPTION:Right Test, Right patient, Right Response: Diagnostic biomarkers and patient pathways\n\nOur Autumn Symposium will look at evolving and novel use of key biomarkers to improve care and patient safety in conditions encountered in, and relevant to many areas of clinical practice. We have secured four expert speakers who will cover “state of the art” aspects of kidney, heart, liver and sepsis biomarkers:Biomarkers in CKD and AKI : muscle mass, frailty and other pitfalls \nProfessor Philip Kalra, Director of Donal O’Donoghue Renal Research Centre and Consultant Nephrologist, Northern Care Alliance\n\nThis talk will cover:\n\nComparison of various eGFR equations : eGFRcreatinine; eGFRcystatin; eGFRcreat-cyst versus gold standard measured GFRUsefulness of cystatin C in CKD evaluationCreatinine muscle index and frailtyEstimation of kidney function in acute illness and the ICULearning points :\n\nLow muscle mass leads to over-estimation of GFR and is linked to frailty and poor prognosisCystatin C has value in more accurate eGFR assessment in certain body types (high and low muscle mass)Many eGFR equations available globally; CKD-EPI 2009 performs well and includes race adjustment\n 'Point-of-care testing  (POCT) for troponin pre-hospital admission'- Title to be confirmed\nMr Phillip Jones, Urgent and Emergency Care Advanced Practitioner, North West Ambulance Service\n \n\nIdentifying liver disease early: biomarkers and beyond\nDr Varindar Athwal, Senior Lecturer and Consultant Hepatologist, Manchester University NHS Foundation Trust\n\nTalk synopsis:\n\nThis talk will discuss the pathogenesis of chronic liver disease and the value of early detection to change disease trajectory. I will discuss the state-of-the-art in fibrosis detection, including current non-invasive tests and limitations. We will discuss how technologies such as artificial intelligence and large datasets have the potential to help identification of those with the most to benefit.\n\nKey learning points:\n\nUnderstand the current non-invasive tests for chronic liver disease.Review the latest biomarkers and pathways that could improve diagnosis of liver disease.Discuss future technologies and innovations with the potential to change how we identify liver disease.\n The role of circulating inflammatory biomarkers to guide antibiotic treatment decisions in sepsis \nProfessor Paul Dark, Vice-Dean for Health and Care Partnerships, Professor of Critical Care Medicine and Consultant, Northern Care Alliance\n\nTalk synopsis:\n\nIn this lecture, Professor Dark will provide an overview of the latest evidence on circulating inflammatory biomarkers from our NIHR-funded UK clinical trials aimed at determining: (1) when to start and (2) when to stop antibiotics for suspected sepsis in adults and children.\n \n\nPRESIDENTIAL ADDRESS by Professor Felicity Stewart, Professor Emerita (Medical Education), University of Manchester\n\nFull details of this CPD-approved meeting will follow soon.\n\nAll attendees will receive a CPD certificate of attendance\n\n
DTSTART:20251015T130000Z
DTEND:20251015T170000Z
LOCATION:MANDEC 3rd Floor, University Dental Hospital, Higher Cambridge Street, Manchester M15 6FH
END:VEVENT
END:VCALENDAR